<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Several studies have suggested an association between specific <z:mp ids='MP_0002055'>diabetes</z:mp> treatment and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the association between <z:chebi fb="0" ids="6801">metformin</z:chebi> use and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality in a prospectively followed cohort </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In 1998 and 1999, 1,353 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were enrolled in the Zwolle Outpatient <z:mp ids='MP_0002055'>Diabetes</z:mp> project Integrating Available Care (ZODIAC) study in the Netherlands </plain></SENT>
<SENT sid="3" pm="."><plain>Vital status was assessed in January 2009 </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> mortality rate was evaluated using standardized mortality ratios (SMRs), and the association between <z:chebi fb="0" ids="6801">metformin</z:chebi> use and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality was evaluated with a Cox proportional hazards model, taking possible confounders into account </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Median follow-up time was 9.6 years, average age at baseline was 68 years, and average A1C was 7.5% </plain></SENT>
<SENT sid="6" pm="."><plain>Of the patients, 570 died, of which 122 died of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The SMR for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality was 1.47 (95% CI 1.22-1.76) </plain></SENT>
<SENT sid="8" pm="."><plain>In patients taking <z:chebi fb="0" ids="6801">metformin</z:chebi> compared with patients not taking <z:chebi fb="0" ids="6801">metformin</z:chebi> at baseline, the adjusted hazard ratio (HR) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality was 0.43 (95% CI 0.23-0.80), and the HR with every increase of 1 g of <z:chebi fb="0" ids="6801">metformin</z:chebi> was 0.58 (95% CI 0.36-0.93) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In general, patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are at increased risk for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
<SENT sid="10" pm="."><plain>In our group, <z:chebi fb="0" ids="6801">metformin</z:chebi> use was associated with lower <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality compared with nonuse of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Although the design cannot provide a conclusion about causality, our results suggest a protective effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality </plain></SENT>
</text></document>